PMID- 15610956
OWN - NLM
STAT- MEDLINE
DCOM- 20050215
LR  - 20181201
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 29
IP  - 1
DP  - 2005 Jan
TI  - Switching depot antipsychotic drug responders to oral olanzapine.
PG  - 141-4
AB  - In an open-label study, 13 patients taking depot antipsychotic medication for 
      greater than 3 years were switched to oral olanzapine. The first 3-month 
      experience has been previously reported. We now describe a second 3-month 
      experience and integrate our observations into a cumulative 6-month report. 
      Monthly, we assessed patients using clinical ratings [Positive and Negative 
      Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Mini-Mental State 
      Exam (MMSE), and Clinical Global Improvement Scale (CGI)] and side effect 
      parameters [Abnormal Involuntary Movement Scale (AIMS), Association for 
      Methodology and Documentation in Psychiatry psychotropic side effect rating scale 
      (AMDP-5), and weights]. Olanzapine patients showed statistically significant 
      improvement (baseline to endpoint sixth month) in GAF (p=0.015), MMSE (p=0.022), 
      CGI improvement, and AIMS (p=0.038). There was no statistically significant 
      change in PANSS, CGI severity, or AMDP-5 overall side effects. Weight gain over 6 
      months averaged 8.9 lb. All patients completed the study. Compliance was 
      estimated at 90%, and 81% of patients chose to continue on the oral olanzapine. 
      One patient was hospitalized at the conclusion of the study. Our findings suggest 
      that clinicians may consider oral olanzapine as a viable alternative to depot 
      antipsychotic medications, balancing clinical improvement in some clinical 
      measures with lack of improvement in other clinical measures; and balancing 
      improvement in abnormal involuntary movements with weight gain and its sequelae.
FAU - Godleski, Linda S
AU  - Godleski LS
AD  - Department of Veterans Affairs Medical Center, Louisville, KY, USA.
FAU - Goldsmith, L Jane
AU  - Goldsmith LJ
FAU - Vieweg, W Victor R
AU  - Vieweg WV
FAU - Zettwoch, Nancy
AU  - Zettwoch N
FAU - Stikovac, Dejzi
AU  - Stikovac D
FAU - Lewis, Susan
AU  - Lewis S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 12794-10-4 (Benzodiazepines)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage/adverse effects/*therapeutic use
MH  - Benzodiazepines/*administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Patient Acceptance of Health Care
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
MH  - Weight Gain/drug effects
EDAT- 2004/12/22 09:00
MHDA- 2005/02/16 09:00
CRDT- 2004/12/22 09:00
PHST- 2004/08/27 00:00 [accepted]
PHST- 2004/12/22 09:00 [pubmed]
PHST- 2005/02/16 09:00 [medline]
PHST- 2004/12/22 09:00 [entrez]
AID - S0278-5846(04)00189-7 [pii]
AID - 10.1016/j.pnpbp.2004.08.009 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):141-4. doi: 
      10.1016/j.pnpbp.2004.08.009.